Source: Annual Congress 2009 - Pulmonary vascular diseases
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Rollins, K. Laliberte, K. Gotzkowsky, M. Wade, R. Grover, D. Mottola (Research Triangle Park, United States Of America). An overview of drug-drug interaction studies conducted with treprostinil. Eur Respir J 2009; 34: Suppl. 53, 3852

Member's Comments

No comment yet.

Related content which might interest you: No significant clinical drug-drug interaction potential with indacaterol Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 No relevant drug-drug interaction between inhaled NVA237 and oral cimetidine Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012 The optimal study design for identifying gene-environment interaction effects in large-scale studies Source: International Congress 2018 – Gene-environment interactions in the omics era Year: 2018 How to design powerful international studies on gene-environment interaction Source: Annual Congress 2008 - WS1 - Gene-environment interactions: challenges and pitfalls in study design, ethical issues and statistical analyses Year: 2008 No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone Source: Eur Respir J, 53 (1) 1801060; 10.1183/13993003.01060-2018 Year: 2019 Drug-drug interaction study between zamicastat and sildenafil in healthy subjects Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 ‘Total PDE4 inhibitory activity‘: a concept for evaluating pharmacokinetic alterations of roflumilast and roflumilast N-oxide in special populations and drug-drug interactions Source: Eur Respir J 2006; 28: Suppl. 50, 436s Year: 2006 Drug-drug interaction study between zamicastat and furosemide in healthy subjects Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 A randomized, crossover study to examine the pharmacodynamics and safety of a new antimuscarinic (TD-4208) in COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Late Breaking Abstract - Pharmacokinetic and pharmacodynamic interactions between components of extrafine formulation of BDP/FF/GB, a novel fixed-dose triple combination for asthma and COPD Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma Source: Eur Respir J 2006; 28: 1042-1050 Year: 2006 The safety of cardioselective ß1-blockers in asthma: literature review and search of global pharmacovigilance safety reports Source: ERJ Open Res, 7 (1) 00801-2020; 10.1183/23120541.00801-2020 Year: 2021 Does the use of inhaled corticosteroids in asthma benefit lung function in the long-term? A systematic review and meta-analysis Source: Eur Respir Rev, 30 (159) 200185; 10.1183/16000617.0185-2020 Year: 2021 Efficacy and safety profile of xanthines in COPD: a network meta-analysis Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Efficacy and safety profile of xanthines in COPD: a network meta-analysis Source: Eur Respir Rev, 27 (148) 180010; 10.1183/16000617.0010-2018 Year: 2018 Methodological issues in therapeutic trials of COPD Source: Eur Respir J 2008; 31: 927-933 Year: 2008 Eliminating in-vitro drug-drug interactions in dual and triple fixed-dose combination therapies using a novel cosuspension metered dose inhaler platform Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 A retrospective observational study: Bidirectional pharmacokinetic interactions between ivacaftor-lumacaftor in cystic fibrosis Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 Are the spacers different in terms of lung bioavailability of salbutamol? An observational comparative study Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Comparative efficacy of umeclidinium/vilanterol versus LABA/LAMA therapies in COPD: A network meta-analysis Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016